This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Various groups in the United States and Europe are now performing bone marrow transplants using tissue whose undesirable components have been reduced in number immunologically so as to avert leukemia recurrence or graft-v-host disease (GVHD).
Transplantation of bone marrow is an established technique in the hematologic restoration of patients with aplastic anemia (JAMA 1981;245:1132-1139, Br Med J 1982;285:835-837), certain leukemias (JAMA [MEDICAL NEWS] 1981;245:2484-2485), and some other disorders who have undergone marrow-ablative therapy. Until recently, however, the only possible donor in such a case was a sibling whose tissue was immunologically compatible with the patient's. According to Rainer Storb, MD, of the Fred Hutchinson Cancer Research Center in Seattle, only 25% to 40% of all patients have such siblings.
But "with the advent of monoclonal antibodies" in the late 1970s, explains Roy Weiner, MD, director of the medical oncology program at the University of Florida College of Medicine, Gainesville, autologous
Zoler ML. New marrow transplant technique aids some cancers. JAMA. 1982;248(18):2213–2215. doi:10.1001/jama.1982.03330180007005
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: